Fondaparinux sodium is the active pharmaceutical ingredient (API) for the anticoagulant drug that inhibits Factor Xa [1].
What is Fondaparinux Sodium Used For?
Fondaparinux sodium is used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. It is also used to prevent blood clots in people who have had surgery, such as hip fracture surgery or knee replacement surgery [1].
How Does Fondaparinux Sodium Work?
Fondaparinux sodium is a synthetic pentasaccharide that selectively inhibits activated Factor X (Factor Xa) [1]. By inhibiting Factor Xa, it breaks the coagulation cascade, preventing the formation of thrombin and thus the formation of a blood clot [1].
When Does Fondaparinux Patent Expiry Occur?
Information regarding the specific patent expiry dates for fondaparinux sodium is available on DrugPatentWatch.com [2]. DrugPatentWatch tracks patent statuses and expiry dates for pharmaceutical ingredients, which can influence market entry for generic alternatives [2].
Can Generic Fondaparinux Sodium Be Manufactured?
The manufacturing of generic versions of fondaparinux sodium is dependent on patent expiry and regulatory approval [2]. Once patents expire, companies can seek to develop and market generic alternatives, provided they meet the necessary quality and efficacy standards set by regulatory bodies [2].
What are the Risks Associated with Fondaparinux Sodium?
The primary risk associated with fondaparinux sodium is an increased risk of bleeding [1]. Other potential side effects include anemia and dizziness [1].